Chongqing Liangjiang Drug R&D Center Co., Ltd.

Liangjiang Drug takes the R&D of innovative drugs and improved new drugs as its core, focuses on disease areas with severe unmet clinical needs such as malignant tumors and drug-resistant antibiotics, gathers top pharmaceutical R&D and management talents from around the world, and is committed to becoming an influential technology-driven pharmaceutical R&D enterprise in Southwest China.
Liangjiang Drug was recognized as a National High-tech Enterprise in 2016. To date, it has undertaken 5 *** scientific research projects and 7 municipal-level science and technology projects; obtained 4 drug clinical registrations; applied for 23 national invention patents (14 authorized) and 22 registered trademarks. It jointly undertook the Western Special Innovation Capacity Building Project of the National Development and Reform Commission. It received approval and acceptance from the Chongqing Economic and Information Commission's Industrial Revitalization Special Project "Independent R&D Institution Construction Project," and possesses multiple innovation platforms and qualifications and honors such as "Chongqing Chemical Drug Analysis Engineering Technology Research Center," "Chongqing Insoluble Drug Engineering Technology Research Center," "Chongqing Drug R&D and Technology Transformation Maker Space," "Postdoctoral Research Workstation," "Intellectual Property Pilot Enterprise," and "Chongqing High-tech Service."
Liangjiang Drug focuses on drug R&D and technological innovation, has complete instrument and equipment conditions and strong independent innovation and development capabilities, possesses a world-class advisory team including Nobel Prize winners, top technical talents from world-renowned universities, and product R&D and operation strength, adopts new drug technology innovation mechanisms, carries out the development, introduction, and technology transformation of high-end pharmaceutical products including drugs and health products, promotes the transformation of pharmaceutical industry achievements and industrial upgrading, promotes domestic biomedical enterprises to participate in market competition from a global perspective, supports new product line layout, and builds an internationalized industrial chain.